The 2025 Directions overhaul asset-liability management for UCBs, setting clear governance, liquidity limits, and IRR controls. Key takeaway: stricter, standardised risk management and reporting ...
AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been granted Breakthrough Therapy Designation (BTD) in the US for adult patients with HER2-positive early breast cancer ...
Investing.com -- AstraZeneca PLC (ST:AZN) and Daiichi Sankyo’s Enhertu has received Breakthrough Therapy Designation from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback